Aquatic Capital Management LLC purchased a new position in shares of Smith & Nephew plc (NYSE:SNN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 41,590 shares of the medical equipment provider's stock, valued at approximately $1,022,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of SNN. Franklin Resources Inc. lifted its position in Smith & Nephew by 16.8% during the 3rd quarter. Franklin Resources Inc. now owns 114,080 shares of the medical equipment provider's stock worth $3,265,000 after acquiring an additional 16,397 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Smith & Nephew by 31.8% during the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider's stock worth $73,000 after purchasing an additional 718 shares during the period. Ridgewood Investments LLC grew its position in Smith & Nephew by 6.1% in the 4th quarter. Ridgewood Investments LLC now owns 75,979 shares of the medical equipment provider's stock valued at $1,868,000 after buying an additional 4,336 shares during the last quarter. Crossmark Global Holdings Inc. increased its stake in Smith & Nephew by 1.2% in the 4th quarter. Crossmark Global Holdings Inc. now owns 114,226 shares of the medical equipment provider's stock valued at $2,808,000 after buying an additional 1,367 shares during the period. Finally, Blue Trust Inc. lifted its stake in shares of Smith & Nephew by 26.0% in the 4th quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider's stock worth $144,000 after acquiring an additional 1,213 shares during the period. 25.64% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. StockNews.com upgraded Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. HSBC downgraded Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. UBS Group cut Smith & Nephew from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. Finally, Hsbc Global Res lowered shares of Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Six research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Smith & Nephew presently has an average rating of "Hold" and an average price target of $28.00.
Check Out Our Latest Research Report on Smith & Nephew
Smith & Nephew Price Performance
SNN stock traded up $0.08 during midday trading on Tuesday, hitting $28.45. 336,190 shares of the stock were exchanged, compared to its average volume of 813,787. The stock's 50-day moving average price is $27.64 and its 200-day moving average price is $26.28. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The stock has a market cap of $12.46 billion, a price-to-earnings ratio of 13.18, a PEG ratio of 1.26 and a beta of 0.68. Smith & Nephew plc has a fifty-two week low of $23.69 and a fifty-two week high of $31.72.
Smith & Nephew Increases Dividend
The company also recently declared a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.447 per share. This represents a dividend yield of 2.5%. The ex-dividend date is Friday, March 28th. This is an increase from Smith & Nephew's previous semi-annual dividend of $0.29. Smith & Nephew's payout ratio is 41.20%.
About Smith & Nephew
(
Free Report)
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Further Reading
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
